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We recently reported the use of PSCl3 for the thiophosphorylation of alkylamines where the resulting N-
thiophosphoramidate ions could be readily S-alkylated (Chem. Commun., 2011, 47, 6156-6158.). Herein 10 
we report the development of this methodology using amino acid, amino sugar, aminonucleoside and 
aniline substrates. The hydrolysis properties of N-thiophosphoramidate ions and their reactivities towards 
alkylating agents are also explored. In addition, we demonstrate the application of our approach to the 
preparation of a small library of compounds, including quinoline-based N,S-dialkylthiophosphoramidates 
which were tested for antileishmanial activity.  15 
Introduction 
Phosphate esters are key intermediates in the transmission of 
genetic material and many other critical cellular processes. 
Structural analogues of these systems have been used widely as 
tools for determining enzyme mechanisms and as inhibitors or 20 
activators of these enzymes. Sulfur-based analogues have been 
used in place of phosphodiesters to both increase and decrease the 
rate of ester bond cleavage. Accelerated cleavage rates are 
offered by S-bridging systems,1 where the thiolate leaving group 
departs more readily than its alkoxide analogue, whereas reduced 25 
cleavage rates are seen for non-S-bridging systems.2 Nitrogen-
bridging phosphodiester mimics, where N-protonation becomes 
possible, have also been generated and studied.3-10 A combination 
of N- and S-bridging systems have seen application in the form of 
phosphate triester mimics that show antiviral activity. These 30 
uncharged, nucleoside-based thiophosphoramidates serve as 
prodrogs which traverse cell membranes, however, within the 
cell, programmed hydrolysis occurs to reveal nucleoside 
monophosphates that go on to interefere with viral replication. 
 Recently, we reported a simple aqueous method for the 35 
preparation of N, S-thiophosphoramidates.11 These 
phosphodiester mimics, with their N- and S-bridges, were 
assembled through the electrophilic action of the reactive 
phosphorylating agent PSCl3 on nucleophilic primary 
alkylamines followed by S-alkylation of the resulting N-40 
thiophosphoramidate ions—an approach that builds on our 
established use of reactive P species in aqueous systems.12-14 Here 
we describe the development of our strategy for 
aminothiophosphorylation, including the use of alkyl, aryl, amino 
acid, amino-sugar and aminonucleoside substrates. We describe 45 
kinetic studies on the pH-dependent hydrolysis properties of N-
thiophosphoramidate ions which were used to inform subsequent 
optimisation of S-alkylation steps. Studies on several S-reactive 
electrophile species and alkylation conditions are also reported, 
along with our efforts towards using bromoacetamides as generic 50 
amine-derived alkylating agents. Finally, our 
thiophosphorylation-alkylation conditions were applied to a 
library of lipophilic amines which were then alkylated with a 
quinoline derivative before being screened for activity against 
Leishmania mexicana, a causative agent of the Neglected 55 
Tropical Disease leishmaniasis.15  
Combined thiophosphorylation-S-alkylation of 
alkyl-, aryl- and biomolecule-derived amines. 
We demonstrated that simple alkylamines are effective substrates 
for PSCl3 under aqueous conditions in the presence of NaOH. 60 
The resulting N-thiophosphoramidate ions can then be alkylated 
effectively using a range of soft alkylating agents (Scheme 1). 
 
Scheme 1 Aqueous N-thiophosphorylation and S-alkylation. 
With the aim of broadening the scope of amine substrate used in 65 
this method we explored the thiophosphorylation and S-alkylation 
of aniline, unprotected phenylalanine, glucosamine and two 5’-
amino-5’-deoxynucleosides.  
Aniline 
We employed a 1.2:1 ratio of aniline 1 to PSCl3 followed by 70 
alkylation of the expected N-thiophosphoramidate ion using 
bromoethanol (Scheme 2). Thiophosphorylation proceeded to a 
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reasonable extent of 62% as determined by 31P NMR 
spectroscopy, with the key signal for thiophosphorylated amines 
usually appearing in the shift range 40-45 ppm. After addition of 
bromoethanol, a combination of 1H and 31P NMR methods 
revealed ~47% conversion to the N, S-thiophosphoramidate 2 (δ ~ 5 
20-25 ppm), and 32% of S-alkylated thiophosphate ion 3 (δ ~ 15-
20 ppm). The remainder of the product mixture was 
predominantly aniline 1 (19%). The use of higher concentrations 
of aniline may have improved conversion to the N-
thiophosphoramidate, and our studies with morpholine have 10 
shown that despite the increased potential for bis- and tris-
aminolysis of PSCl3, this is likely possible. However, on the basis 
of this preliminary result, we did not pursue this optimisation. 
  
Scheme 2  N-Thiophosphorylation and S-alkylation of aniline. 15 
Phenylalanine 
Post-translational phosphorylation of proteins represents a major 
signalling pathway, and access to phosphoproteins and their 
analogues supports the delineation of these key processes. In 
addition, phosphorylation of the carboxyl group of amino acids 20 
serves to activate the carbonyl group for substitution during 
coded protein biosynthesis. Furthermore, phosphonamide systems 
have been widely exploited as transition state mimics for the 
attack of water upon the cabonyl of amides (Figure 1). To date, a 
limited number of examples of aqueous amino acid 25 
phosphorylations have been reported. Metatriphosphate ion 
possesses an activated anhydride structure that has been shown to 
be an effective N-phosphorylating agent for amino acids. In 
addition to N-phosphorylation, in the context of an amino acid, 
the carboxylate group acts as an internal nucleophile, displacing 30 
pyrophosphate ion and forming a cyclic mixed anhydride-
phosphoramidate species. Cyclic phosphate esters show enhanced 
electrophilicity over their acyclic counterparts, and in this guise, 
the cyclic mixed anhydride-phosphoramidates show 
electrophilicity towards water at the phosphoryl centre and 35 
amines at the carbonyl. Histidine side chains of proteins have also 
been successfully modified with thiophosphorylating agents 
(PSCl3 and thiophosphoramidate ion) in order to prepare more 
hydrolytically stable analogues of phosphohistidyl proteins that 
are intermediates in a variety of signalling enzymes.16-18 40 
 With these ideas in mind, we hoped to apply PSCl3 towards the 
primary amino function of phenylalanine and alkylate the 
resulting thiophosphoramidate ion to produce carboxamide 
hydrolysis transition state analogues (Figure 1). 
 45 
Figure 1 Structural resemblance of amide hydrolysis and 
amino acid-N-thiophosphoramidates. 
 Using 1.0 eq phenylalanine, 7.0 eq NaOH and 1.4 eq PSCl3, 
85% N-thiophosphoryaltion was observed by 31P NMR 
spectroscopy (Scheme 3) after removal of inorganic 50 
thiophosphate through selective precipitation. The remainder of 
the P-containing impurites included N-phosphoramidate (~10%) 
and several unidentified species. 
 S-Alkylation was attempted in D2O using methyl iodide, 
however, only 24% conversion to the N,S-55 
dialkylthiophosphoramidate 4 was observed. The remainder of 
the P-containing materials included significant quantites of the N-
phosphoramidate and phosphate ion. 
 
Scheme 3 N-Thiophosphorylation–S-alkylation of 60 
phenylalanine. 
 Mass spectrometric analysis of the N-thiophosphorylation 
mixture also revealed significant quantities of N-phosphoramidate 
5 plus Phe-Phe dimer 6, however, the analysis was performed 
under acidic conditions, which were likely to encourage 65 
desulfurisation. 
 Taken together, these pieces of evidence strongly support the 
idea of intramolecular assistance of the carboxyl group in the 
decomposition of the S-alkylated thiophosphoramidate (or the 
protonated thiophosphoramidate ion), where the cyclic mixed 70 
anhydride intermediate 7 likely facilitates the formation of 
several of the decomposition products (Scheme 4). 
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Scheme 4 Possible intramolecular reactions of phenylalanine-
based thiophosphoramidate systems. 
Glucosamine 
Phospho-sugar systems play many biological roles and we hoped 5 
that we would be able to gain access to phospho-sugar mimics 
using our approach. Glucosamine was chosen as a readily 
avialable model substrate for our preliminary study. Others have 
investigated aqueous sugar phosphorylation procedures using 
metatriphosphate ion and its imino analogue, however, yields 10 
were low. The preparation of sugar phosphoramidates that go on 
to afford a phosphosugars has also been investigated, and good 
yields (79%) were reported. 
 A preliminary thiophosphorylation experiment using a 1:1 
ratio of glucosamine 8 to PSCl3 gave a rewarding ~90% 15 
conversion (estimated from a signal ~45.5 ppm in the 31P NMR 
spectrum) to the N-thiophosphoramidate 9. Over a time course of 
~1 h, however, this signal dimished, with new signals appearing 
at similar chemical shifts. At present, we are not able to assign 
these, however, they are consistent with thiophosphoryl groups 20 
that have not been S-alkylated. Indeed, they may represent 
phosphorothioates that have arisen through intramolecular 
isomerisation. Despite this process, we proceeded with S- 
alkylation using MeI. This led to a majority of the P-containing 
product mixture being converted to S-methylated  inorganic 25 
phosphate ion 10. The large proportion of N-P bond scission 
suggests that once alkylated, intramolecular reaction facilitates 
this cleavage, unlike simple N,S-dialkyl thiophosphoramidates, 
which appear to be stable under the reaction conditions. A 
tentative decomposition mechanism for the glucosamine system 30 
is presented in Scheme 5. The key difference between this system 
and the Phe system is the potential for intramolecular acid 
catalysis via the 1-OH group, which, as an acetal, could act as an 
acid at the relatively high pHs used for thiophosphorylation (and 
alkylation). Smaller signals ~10-12 ppm are consistent with N-35 
phosphoramidates that result from desulfurisation processes, 
where the two signals may signify the α- and β-anomers. On the 
basis of these preliminary results, we did not explore this system 
further, however, delivery of such a reactive phosphoryl donor to 
an enzyme active site may offer a useful tool for enzyme 40 
labelling or capture, and may also offer uses as a synthetic 
phosphorylation tool. 
 
Scheme 5 N-Thiophosphorylation–alkylation of glucosamine 
and potential pathways for decomposition. 45 
5’-Amino-5’-deoxyguanosine and  5’-Amino-5’-
deoxyadenosine 
Nucleoside phosphates are ubiquitous in biological systems, and 
a range of N-containing and S-containing phosphate mimics have 
been reported, with uses in mechanistic studies and 50 
antisense/siRNA applications. We have already reported the 
alkylation of N-thiophosphoramidate using a nucleoside-5’-
iodide, and reasonable conversions were observed. Alkylation 
with the nucleoside-5’-iodide, however, proved to be very slow in 
comparison to other alkylating agents (see below). With this in 55 
mind, we sought to explore the N-thiophosphorylation of 5’-
amino-5’-deoxynucleoside substrates and their subsequent 
alkylation. 
 We prepared adenosine and guanosine aminonucleosides 11a-
b using established procedures. The adenosine system 11b was 60 
isolated as its hydrochloride salt, thus an additional equivalent of 
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NaOH was employed during thiophosphorylation. Alkylations 
were then performed using MeI, and, ion both cases, the S-
alkylated aminonucleoside-N-thiophosphormaidates 12a-b were 
formed at conversions levels ~70%. Given that unprotected 
nucleosides were employed, this level is impressive, however, 5 
chromatographic purification was necessary (see ESI) in order to 
confirm the identity of all the reaction products.  
 
Scheme 6 N-Thiophosphorylation–alkylation on 5’-
aminonucleosides. 10 
The desired thiophosphoramidate products eluted ~35-40 min 
which correponded to ~100-140 mM TEAB. The areas under the 
absorbance–elution time profiles were also used to estimate 
conversion to the desired products, and the values were in 
agreement with the observations from 1H and 31P NMR 15 
spectroscopies. 
S-Alkylation 
In order to achieve effective alkylation, we explored the effects of 
pH, stoichiometry, reaction time and temperature on model 
substrates. In addition, we explored the kinetics of alkylation of a 20 
range of thiophosphoramidate ions and alkylating agents. The 
stability of the S-alkylated thiophosphoramidates was also 
explored. These results are summarised in the following sub-
sections. 
Stability of N-thiophosphoamidate ions 25 
 In line with N-phosphoramidates, we expected N-
thiophosphoramidates to display greater stability at higher pHs. 
In order to explore this idea, we conducted 31P NMR kinetic 
studies using ethanolamine-N-thiophosphoramidate 13 as 
substrate. The use of 31P NMR spectroscopy allowed us to 30 
monitor the decomposition of the ethanolamine-N-
thiophosphoramidate and to gain insight into the identities of the 
resulting hydrolysis products through the use of chemical shift 
and signal multiplicity data. The substrate was dissolved in 4 M 
or 0.5 M buffer, the water was removed by lyophilisation and the 35 
residue was redissolved in D2O. This provided solutions where 
~90% of the labile protons had been exchanged for deuterium to 
enable a deuterium lock signal to be used. The use of 4 M buffer 
solutions, ensured the pH changes observed during kinetic 
experiments were small, however, the presence of large 40 
concentrations of sodium ions caused problems with the 
measurement of pH. This manifested itself in the form of 
deviation from the expected gradient of –1 in the log kobs-pH plot 
for pH>8. On this basis, some of the experminets at higher pHs 
were repeated using 0.5 M buffers. Under these conditions, 45 
greater changes in pH (0.2-0.5) were observed during the courses 
of the kinetic experiments, however, a gradient of –1 was 
observed for the log kobs-pH data at higher pHs (Figure 2).  
Caution should also be taken in terms of the interpretation of 
measured pH values where the extent of deuteriation within the 50 
buffer is not clearly defined. 
 
Figure 2 31P NMR spectroscopy study of the hydrolysis of 
ethanolamine-N-thiophosphoramidate ion as a function of pH. 
Red circles represent rate constants for the disappearance of 55 
ethanolamine-N-thiophosphoramidate ion (closed, stronger 
buffers; open, weaker buffers); black triangles represent the 
appearance of phosphate ion (a similar trace for the 
disappearance of thiophosphate ion was also observed; not 
shown); and blue squares represent the appearance of 60 
ethanolamine-N-phosphoramidate ion.  
Closer analysis of the 31P NMR spectra shows that in addition of 
P-N scission to give amine and inorganic thiophosphate ion, 
desulfurisation of both the N-thiophosphoramidate substrate 13 
and thiophosphate ion occurs (Scheme 7) to give N-65 
phosphoramidate 14 and phosphate ion, respectively.9, 10, 19 
Desulfurisation of the N-thiophosphoramidate ion, however, was 
only detectable for 7<pH<9, whereas desulfurisation of 
thiophosphate ion was seen across the profile. Rate constants for 
the processes discussed above have been estimated, however, the 70 
compromises made in terms of the use of buffers to facilitate the 
use of 31P NMR spectroscopy, mean that these rate constants 
should only be considered on an order-of-magnitude basis. On the 
pH plateaux, disappearance of thiophosphoramidate shows a rate 
constant of ~ 4×10–2 s–1; appearance of phosphate, 5×10–4 s–1; and 75 
appearance of phosphoramidate, ~6×10–5 s–1. Taken together, 
however, these data give clear evidence that N-
thiophosphoramidate species display similar pH-reactivity 
properties to their oxy-analogues, and the use of higher pH would 
appear to be the most relaible pathway towards S-alkylation. In 80 
addition, these data align well with the findings of Ora et al. and 
their studies on closely related systems. 
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Scheme 7 Hydrolytic breakdown products of ethanolamine-N-
thiophosphoramidate. 
Stability of N,S-dialkylthiophosphoramidates 
To gain an appreciation of the stability of N,S-dialkyl 
thiophosphoramidates, we performed 31P NMR spectroscopy-5 
based studies on N-benzylamino-S-n-propylthiophosphoramidate 
at pH ~7.5 and ~5.2. The pH of 7.5 was chosen to be close to 
physiological pH, whereas the pH 5.2 provides a situation where 
N-protonation is more likely, and reactivity is expected to be 
higher. In addition, the lower pH aligns with the conditions used 10 
for amastigote testing, which will be discussed below. The 
samples were incubated at 37 °C and 31P NMR spectra were 
recorded periodically. No changes the forms of the spectra were 
observed over the course of 16 h. On the basis of these results, 
where we would expect to be able to detect 5% degradation 15 
reliably using the NMR method, we predict half-lives >200 h in 
both cases. Whilst this picture suffices for the development of our 
synthetic procedures, further detailed kinetic studies will be 
required. 
Bromoacetamides as alkylating agents 20 
In order to expand the range of potential alkylating agents 
available for elaboration of N-thiophosphoramidate ions, we 
explored the use of a heterobifunctional cross-linking agents. We 
envisioned 15 being able to react selectively with 
thiophosphoramidate ions to produce activate acylating agents 16 25 
that could be further reacted with readily accesible amines to 
produce mixed phosphoryl-acyl systems 17 that may serve as 
pyrophosphate mimics (Scheme 8). Our earlier experiences with 
a thiophosphate anion-based system (uridine-5’-
monophosphorothioate, UMPS), suggested that this strategy 30 
could offer a convenient  aqueous route to these species.20 
 
Scheme 8 (A) Disconnection strategy for thiophosphoramidate-
bromoacetate ester ligation of two amines. (B) Structural 
resemblance of thiophosphoryl-acetamide system to 35 
pyrophosphate. 
Based on our earlier work with thiophosphates, we performed 
exploratory studies on the use of p-nitrophenyl-, m-nitrophenyl 
and phenyl-bromoacetate esters 15a-c respectively. Our aim was 
to balance hydrolysis of the activated ester against the desired 40 
aminolysis process by tuning the reactivity of the phenolate 
leaving group. We used benzylamine as a model substrate for 
thiophosphorylation given that we had observed this process to 
proceed quantitatively. The second amine, RNH2, was either the 
model system, allylamine, or the more challenging 5’-amino-5’-45 
deoxyguanosine (Scheme 9). 
 
Scheme 9 Amine-amine ligation via thiophosphorylation-
bromoacetate ester cross-linking. 
After each reaction, excess amine RNH2 was removed by 50 
increasing pH followed by extraction with organic solvent. The 
pH was then reduced to facilitate protonation of the phenolate 
leaving groups by extraction into organic solvent. In all cases, the 
majority of material was converted to the desired 
thiophosphoramidate-acetamide products 16 and 17.  55 
 In order to confirm the identity of the guanosine-derived 
product 16, ion exchange chromatography was carried out. As 
seen for the N-thiophosphorylated aminonucleoside systems (see 
above), the desired thiophosphoramidate product 16 eluted ~35-
40 min which corresponded ~90 mM TEAB (see ESI). The 60 
conversion level estimated by measuring the area under the 
absorbance curve in the elution profile correlated well with 
observations from 1H and 31P NMR spectroscopies. 
These preliminary studies illustrate that the thiophosphorylation-
bromoacetate route could offer a simple route towards 65 
nucleoside-based systems. Further optimisation of conditions, 
reaction times and the choice of phenolate leaving group should 
facilitate improvements. 
Nucleophilicity of thiophosphoryl systems 
During our alkylation studies, we observed that some alkylations 70 
appeared more sluggish than others, thus we sought to explore 
these observations through kinetic studies. In addition to being 
sensitive to the nature of the electrophile, we expected the 
kinetics of alkylation to vary as a function of the nature of the N-
alkyl portion of the thiophosphramidate. We studied the progress 75 
of a series of alkylations reaction using 31P NMR spectroscopy 
using ethanolamine-N-thiophosphoramidate 13, benzylamine-N-
thiophosphoramidate 18, and, as a comparison, inorganic 
thiophosphate ion as nucleophiles. The added electrophiles were 
bromoethanol and 5’-deoxy-5’-iodoguanosine 1 (Scheme 10). 80 
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Scheme 10 Thiophosphoryl systems and alkylating agents used 
in S-alkylation kinetic study. 
Alkylations were performed in the presence of a significant 
excess of alkylating agent to facilitate first order kinetic analyses. 5 
Using the reactive bromoethanol system, alkylations proceeded 
rapidly, thus we were unable to derive kinetic data. With the less 
reactive nucleoside system, however, bimolecular rate constants, 
k2, of 4×10–5, 2.5×10–4 and 3.3×10–4 M–1s–1 were obtained for 
ethanolamine-N-thiophosphoramidate 13, benzylamine-N-10 
thiophosphoramidate 18 and inorganic thiophosphate ion, 
respectively. These data confirm that the nature of the substituent 
on the thiophosphoryl group can have a significant effect on 
alkylation kinetics. 
The nucleophilicity of  thiolate ions can be measured 15 
quantitatively, and we would expect these values to be similar in 
nature to thiocarboxylate systems studies by Mayr and co-
workers.21 We are currently exploring these values. 
Preparation of N,S-dialkylthiophosphoramidate 
libraries using lipophilic alkylamines 20 
To prove the general applicability of the method, we preparaed a 
small generic library of N,S-dialkyl thiophosphoramidates 20-
33a-c in a simple, rapid manner where the only form of 
purification was extraction of excess alkylating agent followed by 
removal of the aqueous solvent. All amines were hydrophobic in 25 
nature, and some of the reaction mixtures were heterogeneous.  
 
Table 2. Preparation of a library of N,S-dialkyl thiophosphoramidates and 
control compound. 
 30 
 
entry product  conversion level, 
% 
20 
 
a 81a, 60 b, 54c 
b 97a, 97 b, 92c 
c 98a, 100 b, 100c 
21 
 
a 79 a, 80 b 
b 98 a, 96 b  
c 98 a, 95 b 
22 
 
a 75 a, 68 b 
b 95 a, 97 b 
c 98 a, 98 b 
23 
 
a 90 a, 90 b 
b 92 a, 94 b 
c 93 a, 94 b 
24 
 
a 93a, 90b 
b 94a, 97b 
c 97a, 98b 
 
25 
 
a 61a, 80b 
b 99a, 100b 
c 97a, 94b 
 
26 
 
a 65 a, 65 b 
b 91a, 90b 
c 67a, 60b 
27 
 
a 91a, 95b 
28 
 
a 93a, 96b 
29 
 
a 94a, 96b 
b 95a, 92b 
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30 
 
a 87a, 75b 
c 95a, 82b 
31 
 
a 75a, 78b 
c 79a, 87b 
32 
 
a 81a, 67b 
c 91a, 90b 
33 
 
a 90a, 92b,84c 
c 96a, 96b,100c 
34 
 
95a, 93b 
 
a Determined by 31P NMR spectroscopy. b Determined by 1H NMR 
spectroscopy. c Determined by 19F NMR spectroscopy. 
Alkylating agents were represented by benzyl chloride, n-propyl 
iodide and a quinoline system. The simple alkyl systems served 
to illustrate the usage of a reactive benzyl system and a simple 5 
alkyl system. The quinolines, on the other hand were designed by 
analogy with quinoline-based sulfamidates that have been 
successfully applied as anti-parasite agents. The syntheses of the 
sulfonamides were, however, by way of organic solvent-based 
procedures where laborious purification procedures were 10 
required. We hoped that the similar geometric properties of the 
thiophosphoramidate group may offer an alternative to the 
sulfonamide where product mixture could be used directly from 
aqueous synthetic procedures without isolation.  
Testing Antileishmanial Activities 15 
Quinoline-substituted sulfonamides have been reported as 
potential anti-leishmanial agents (Figure 4).22, 23 
 
Figure 4 Quinoline-based sulfonamides used in 
antileishmanial testing studies. 20 
Owing to the close structural homology of the 
thiophosphoramidate and sulfonamide groups, we prepared 
quinoline-based thiophosphoramidate derivatives 20-33a. In 
addition, phosphorothiolate-quinoline system 34 was prepared as 
a control that represents the common hydrolysis product expected 25 
from P-N scission. We tested these systems for activity againist 
both mammalian stage amastigote and insect stage promastigote 
forms of the Trypanosomatid Leishmania mexicana using 
established protocols.24 Unfortunately, there were no clear signs 
of activity of these agents. In the case of amastigotes, we found 30 
that the quinoline systems were quite sensitive to the acidic 
nature of the specialist growth media, and showed significant 
decomposition over a timescale of hours. This contrasts with our 
findings for other systems, and we attribute this difference to the 
possibility of intramolecular general acid catalysis in the 35 
quinolines (Scheme 11). 
 
Scheme 11 Potential intramolecular mechanism accounting for 
the instability of quinoline-based thiophosphoramidates. 
 Promastigote tesing also failed to demonstrate antileishmanial 40 
activity, thus we must conclude that N-alkyl-S-(methylene(8-
quinolyl)) thiophosphoramidates are not effective against 
Leishmania mexicana, despite their structural resemblance to 
successful sulfonamide compounds. 
Conclusions 45 
Aqueous aminothiophosphorylation offers clean conversion to 
thiophosphoramidate anions when used in conjunction with 
nucleophilic, simple alkylamines, however, aryl systems have 
proven less successful. Unprotected amino acid, sugar and 
nucleoside systems showed varying degrees of effectiveness, with 50 
the aminonucleoside systems showing significant promise and 
scope for improved performance. In these cases, 
thiophosphorylations proceeded, in most cases, smoothly, 
however, on S-alkylation, decomposition was seen. In all cases, 
mechanisms involving intramolecular assistance can be 55 
postulated, and it is these that we believe lead to the 
decomposition in these systems. 
 The straightforward assembly of simple liphophilic systems 
using PSCl3 allowed us to rapidly assemble a library of 
compunds, and, although the quinoline systems presented specific 60 
stability issues, the approach proved effective in facilitating swift 
access to aqueous solutions of library molecules that were 
amenable to biological testing without needing extensive 
purification. 
Experimental 65 
Attempted thiophosphorylation-alkylation of aniline (towards 
2, 3) 
Aniline (1.2 eq, 251 µL, 2.76 mmol) was mixed with aqueous 
sodium hydroxide (5 eq of a 1 M aqueous solution, 11.5 ml, 11.5 
mmol) and water (1.48 ml) in a 50 mL round bottomed flask with 70 
indentations aimed towards inducing turbulent mixing. The 
mixture was cooled on an ice-water bath, thiophosphoryl chloride 
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(1.0 eq, 232 µL, 2.3 mmol) in THF (7 mL) was added dropwise 
over the course of 10 min. and the mixture was stirred for an 
additional 15 min. Bromoethanol (2 eq, 326 µL, 4.6 mmol) was 
added and the mixture was stirred for 22 h while maintaining 
pH~9 through periodic additions of 1 ml aliquots of 1 M NaOH 5 
solution. The mixture was then extracted with diethyl ether 
(3 × 10 mL) to remove excess aniline, PSCl3, THF and 
bromoethanol, and the aqueous layer was concentrated by 
lyophilisation before being subjected to analysis. The conversion 
to N-thiophosphoramidate was estimated by 31P NMR 10 
spectroscopy before addition of bromoethanol (see ESI). After 
addition of the alkylating agent, conversion was estimated using 
31P NMR spectroscopy (47%) and 1H NMR spectroscopy (41%). 
The other impurities present were aniline 19% and alkylated 
inorganic thiophosphosphate 31% by both 31P NMR and 1H NMR 15 
spectroscopy. δH(400 MHz; D2O) 7.26 (2 H, t, J 7.9, m-Ar-H), 
7.09 (2 H, d, J 8.0, o-Ar-H), 6.99-6.90 (1 H, m, p-ArH), 3.56 (2 
H, t, J 6.4, CH2OH), 2.78-2.65 (2 H, m, SCH2); δP(162 MHz; 
D2O) 18.7 (t, 3JH-P 13.4, NPS); δC(101 MHz; D2O) 141.7, 129.6, 
121.3, 118.2 (d, 3JC-P 6.7, CHCNH), 61.6 (d, 3JC-P 4.7, CH2OH), 20 
32.5 (SCH2); m/z (ES–) 232.0203 (M–H. C8H11NO3PS requires 
232.0203). 
Attempted thiophosphorylation-alkylation of phenylalanine 
(towards 4) 
D/L-phenylalanine (1 eq, 2.3 mmol, 380 mg) was dissolved in 25 
aqueous sodium hydroxide (7 eq of a 5 M aqueous solution, 3.22 
ml, 16.1 mmol) in a 50 mL round bottomed flask with indents in 
an ice bath. Thiophosphoryl chloride (1.4 eq, 327 µL, 3.22 mmol) 
in THF (4 mL) was added dropwise to the mixture over the 
course of 10 min. After 1 h of stirring, inorganic thiophosphate 30 
ion arising from hydrolysis of the excess PSCl3 was removed by 
applying methanol precipitation.25 The residual supernatant 
solution was concentrated in vacuo before being freeze-dried to 
remove water and being subjected to NMR analysis. The crude 
phenylalanine thiophosphoramidate (0.5 mmol, 130.5 mg) was 35 
dissolved in D2O (0.5 ml) and MeI (0.5 mmol, 31 µL) was added 
directly to the NMR. The sample was subjected to NMR analysis 
after 20 h. Analysis after thiophosphorylation; δH(400 MHz; 
D2O) 7.34-7.02 (5 H, m, Ar-H), 3.76 (1 H, ddd, J 12.4, 7.9, 4.5, 
CH), 3.06 (1 H, dd, J 13.1 and 4.5, CHH), 2.79 (1 H, dd, J 13.1 40 
and 7.9, CHH); δP(162 MHz; D2O) 42.3 (d, 3JH-P 12.5, NPS); m/z 
(ES+) 262.03 (M + H+); m/z (ES–) 244.0383 (phosphoramidate i.e. 
loss of S, (M–H). C9H11NO5P requires 244.0380). Analysis after 
addition of MeI; δH(400 MHz; D2O) 7.53-7.05 (6 H, m, Ar-H), 
3.90-3.68 (1 H, m, CH), 3.21-3.07 (2 H, m, CH2), 1.67 (3 H, d, J 45 
13.3, SCH3); δP(162 MHz; D2O) 25.1 (d, 3JH-P 12.8, NPS). 
Attempted thiophosphorylation-alkylation of glucosamine 
(towards 9,10) 
Glucosamine hydrochloride (1.0 eq, 496 mg, 2.3 mmol) was 
dissoved in aqueous sodium hydroxide (6 eq of a 1 M aqueous 50 
solution, 13.8 ml, 13.8 mmol) in a 50 mL round bottomed flask 
with indents in an ice bath. Thiophosphoryl chloride (1.0 eq, 232 
µL, 2.3 mmol) in THF (7 mL) was added dropwise to the mixture 
over the course of 10 min. After 1 h of stirring, the conversion to 
thiophosphoramidate was estimated by 31P NMR spectroscopy 55 
MeI (2.0 Eq, 4.6, 286 µL) was added and the mixture was stirred 
for  a further 1 h and subjected to 31P NMR spectroscopy analysis 
to assess S-alkylation. Analysis after thiophosphorylation; δP(162 
MHz; D2O) 45.6 (NPS). After addition of MeI, the majority of 
material appeared to be converted to S-methylthiophosphate 10; 60 
δP(162 MHz; D2O) 19.3 (d, 3JH-P 11.3, OPSMe). 
Thiophosphorylation of 5’-amino-5’deoxyguanosine or 5’-
amino-5’deoxyadenosine and alkylation with MeI or BnCl 
5’-Amino-5’-deoxyguanosine25, 26 (1 Eq, 0.23 mmol) or 5’-
Amino-5’-deoxyadenosine dihydrochloride27 (1 Eq, 0.23 mmol) 65 
was dissolved in a mixture of aqueous sodium hydroxide (5 eq of 
a 1 M solution, 1.15 mmol for G; 7 eq, 1.61 mmol for A) and 
water (148 µL for G, 0 µL for A) in a 50 mL round bottomed 
flask with indents in an ice bath. Thiophosphoryl chloride 
(1 Eq, 23.2 µL, 0.23 mmol) in THF (0.7 mL) was added dropwise 70 
to the aqueous solution over the course of 10 min. and the 
mixture was then stirred for a further 1 h. Methyl iodide (2 Eq, 
28.6 µL, 0.46 mmol) and additional aqueous sodium hydroxide 
solution (1 Eq) were added to the flask and stirring was continued 
for 1 h. The excess of alkylating agent was removed by ether 75 
extraction (3 × 10 mL). The residual aqueous solution was then 
lyophilised and the residues were analysed (see crude 1H and 31P 
NMR spectra in ESI). The crude samples were dissolved in a 50 
mM TEAB buffer, pH 7.5 (5 mL) and purified on DEAE 
Sepharose FF column (50 mL, 10 × 3 mm, 3 mL/min), running 80 
TEAB buffer gradient 50-200 mM. Fractions were pooled and 
lyophilised before confirmation of their identities by 1H and 31P 
NMR spectroscopies. The triethylammonium salts of the 
compounds were dissolved in water (5 mL) and passed through a 
Na-Dowex 50W×2, 200-400 (50 mL, 30 × 2 mm, 3 mL/min) 85 
column, with water as the mobile phase. The fractions containing 
products, detected via UV trace (254 nm), were collected, 
lyophilised and spectroscopic analyses were performed on the 
residues. 
11a 90 
 
δH(700 MHz; D2O) 7.71 (1 H, s, 8-H), 5.66 (1 H, d, J 7.8, 1’-CH), 
4.98-4.94 (1 H, m, 2’-CHOH), 4.31-4.28 (1 H, m, 3’-CHOH), 
4.22-4.19 (1 H, m, 4’-CH), 3.06-2.99 (2 H, m, 5’-CH2), 1.97 (3 
H, d, J 13.0, CH3S); δP[1H](283 MHz; D2O) 26.4-26.1 (m, 95 
NHPS); δC(176 MHz; D2O) not assigned owing to low spectrum 
intensity; m/z (ES–) 391.0594 (M–H. C11H16N6O6PS requires 
391.0595). 
11b 
 100 
δH(700 MHz; D2O) 8.20 (1 H, s, 2-H), 8.08 (1 H, s, 8-H), 5.88 (1 
H, d, J 6.6, 1’-CH), 4.76 (1 H, t, J 5.4, 2’-CHOH), 4.33-4.29 (1 
H, m, 3’-CHOH), 4.17-4.13 (1 H, m, 4’-CH), 3.13-3.00 (2 H, m, 
5’- NH2CH2), 1.95 (3 H, d, J 13.1, CH3S); δP[1H](283 MHz; 
D2O) 26.1-25.8 (m, NHPS); δC(176 MHz; D2O) 155.6, 152.8, 105 
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148.9, 140.8, 140.6, 119.0, 87.7 (1’-CH), 85.1 (d, 3JC-P 8.7, 4’-
CH), 73.1 (2’-CHOH), 71.1 (3’-CHOH), 43.3 (5’-NH2CH2), 11.6 
(d, 2JC-P 3.4, CH3S); m/z (ES–) 375.0643 (M–H. C11H16N6O5PS 
requires 375.0646). 
Kinetic studies on the decomposition of ethanolamine-N-5 
thiophosphoroamidate 13 
Buffers were prepared using CAPS (pH 10.5 and 10.17), CHES 
(pH 9.81, 9.44 and 9.06), EPPS (pH 8.44 and 8.00), HEPES (pH 
7.50 and 7.10), MES (pH 6.60, 6.00 and 5.88) and acetate (pH 
4.80 and 4.66) systems where the pHs were adjusted by the 10 
addition of hydrochloric acid or hydroxide solutions (see ESI). 
Crude, lyophilised ethanolamine thiophosphoroamidate 13 
(30 mg) was dissolved in a buffer solution (0.5 M, 4 mL or 0.5 
mL, see ESI) and the mixture was lyophilised. The lyophilised 
solid was then dissolved in D2O (0.5 mL), a pH meter reading 15 
was taken and the mixture was transferred to a NMR tube. Owing 
to the fact that a rigorous deuterium exchange was not performed, 
the measured pD value could not be converted directly to a pD 
value, however, for the purposes of this preliminary study, the 
uncertainty in these values (~0.1 pD units) was deemed 20 
acceptable. The NMR tube containing the buffered substrate was 
then heated to 50 °C in the NMR machine magnet, and spectra 
were acquired every 30 (CAPS, CHES, EPPS, HEPES), 15 
(MES), 10 (acetate buffer) or 8 (citric buffer) minutes. 
The intensities of the peaks corresponding to the 25 
thiophosphoroamidate, normalised with the highest intensity peak 
in the spectra, set to have the value 1, were plotted as a pseudo 
first order function of time and least squares fittings were 
performed against an exponential decay curve It= I0e–kt. 
Bromoacetamide cross-linker 30 
Use of benzylamine-N-thiophosphoramidate 18 with 
phenylbromoacetates 15a-b and allyl amine or 5’-amino-5’-
deoxyguanosine 
Benzylamine (1 Eq, 25 µL, 0.23 mmol) was thiophosphorylated 
using our established procedure. Allylamine (2 Eq, 32 µL, 35 
0.46 mmol) or 5’-amino-5’deoxyguanosine 
(1 Eq, 65 mg, 0.23 mmol) was added to aqueous/THF solution of 
the thiophosphorylated benzylamine and mixed for several 
minutes, before the phenylbromoacetate ester (1 Eq, 0.23 mmol) 
was added. After 15 minutes of vigorous stirring, the pH of the 40 
mixture was adjusted using 50 mM hydrochloric acid to the 
approximately the pKa of the phenol leaving group. The solution 
was extracted with ethyl acetate (3 × 10 mL), the pH was adjusted 
to pH 9 and the extraction was performed using chloroform 
(3 × 10 mL) in an atempt to remove excess amine. The aqueous 45 
sample was lyophilized and the dry solid was analysed and 
purified (nucleoside). 
17 
 
δH(400 MHz; D2O) 7.45-7.22 (5 H, m, C6H5), 5.85-5.74 (1 H, m, 50 
CH2=CH), 5.20-5.10 (2 H, m, CH2=CH), 4.00 (2 H, d, J 10.9, 
CH2NH), 3.72 (2 H, dt, J 5.1 and 1.6, NHCH2), 3.33 (2 H, d, J 
12.9, SCH2); δP[1H](162 MHz; D2O) 22.0-21.6 (m, NHPS); 
δC(101 MHz; D2O) 172.4 (d, 3JC-P 3.6, C=O), 140.6 (d, 3JC-P 7.6, 
CCH2NH), 133.6 (CH=CH2), 128.9, 128.8, 127.4, 116.4 55 
(CH2=CH), 45.6 (PhCH2NH), 42.2 (CH2CH=CH2), 33.7 (SCH2); 
m/z (ES–) 299.0627 (M–H. C12H16N2O3PS requires 299.0624). 
16 
 
The crude sample (50 mg) was dissolved in a 50 mM TEAB 60 
buffer, pH 7.5 (5 mL) and purified on DEAE Sepharose FF 
column (50 mL, 10 × 3 mm, 3 mL/min), running TEAB buffer 
gradient 50-200 mM. Fractions were pooled and lyophilised, and 
the main peak in the UV trace was found to contain the desired 
product (87% by 31P NMR spectroscopy, 78% by 1H NMR 65 
spectroscopy). The triethylammonium salt of the compound was 
dissolved in water (5 mL) and passed through a Na-Dowex 
50W×2, 200-400 (50 mL, 30 × 2 mm, 3 mL/min) column, with 
water as the mobile phase. The fractions containing product, 
detected via UV trace (254 nm), were collected and lyophilised. 70 
The purity after cation exchange chromatography was estimated 
to be 80 % by 31P NMR spectroscopy and 68% by 1H NMR 
spectroscopy). δH(700 MHz; D2O) 7.74 (1 H, s, 8-H), 7.10-6.99 
(5 H, m, Ar-H), 5.58 (1 H, d, J 4.5, 1’-CH), 4.47 (1 H, app t, J 
5.0, 2’-CHOH), 4.17 (1 H, app t, J 5.3, 3’-CHOH), 4.11-4.07 (1 75 
H, m, 4’-CH), 3.71-3.60 (2 H, m, CH2NH), 3.49 (1 H, dd, J 14.3 
and 7.4, 5’-CH2), 3.43 (1 H, dd, J 14.6 and 3.4, 5’-CH2), 3.29-
3.17 (2 H, m, SCH2); δP[1H](162 MHz; D2O) 22.7-22.5 (m, 
NHPS); δC(101 MHz; D2O) 172.9 (d, 3JC-P 2.6, C=O), 158.7, 
153.7, 151.1, 140.2, 137.4, 128.8, 128.5, 128.2, 127.5, 127.3, 80 
126.9, 126.7, 116.5, 87.7 (1’-CH), 82.0 (4’-CH), 73.4 (2’-
CHOH), 70.9 (3’-CHOH), 45.0 (CH2NH), 41.4 (5’-CH2), 33.4 (d, 
2JC-P 12.4, SCH2); m/z (ES–) 524.1127 (M–H. C19H23N7O7PS 
requires 524.1123). 
Kinetic study of the alkylation of thiophosphate ion using 5’-85 
deoxy-5’-iodoguanosine 19. 
A stock solution of 100 mM NaOH with 10 % D2O was made 
with NaOH (0.5 ml, 1 M), H2O (4 ml) and D2O (0.5 ml). 5'-iodo 
5'-deoxyguanosine (19 mg, 0.05 mmol) and tribasic sodium 
thiophosphate (0.09 g, 0.5 mmol) were dissolved in the stock 90 
NaOH solution (0.5 ml). The solution was transferred into a 
NMR tube and reaction progress at 50 °C was monitored in the 
NMR spectrometer by 31P NMR spectroscopy (202 MHz, 128 
repetitions). Two runs were performed with time points being 
taken either every 1 h or every 10 min. 95 
Kinetic studies of the alkylations of benzylamine-N- 
thiophosphoroamidate 18 and ethanolamine-N-
thiophosphoroamidate 13 ion with bromoethanol and 5’-
deoxy-5’-iodoguanosine 19. 
5’-iodo-5’-deoxyguanosine 19 (19 mg, 0.05 mmol) or 2-100 
bromoethanol (3.5 µL, 0.05 mmol) was measured directly into an 
NMR tube. Crude benzylamine-N-thiophosphoroamidate (101.5 
mg) or ethanolamine-N-thiophosphoroamidate (78.5 mg) was 
dissolved in D2O (0.5 mL) and added to the alkylating agent. The 
mixture was then subjected to 31P NMR spectroscopic analyses at 105 
N
H
P
S
O O H
N
O
N
H
P
S
O O
O
G
O
OHOH
H
N
Na
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |   10 
50 °C over a period of 12 h, with spectra being collected every 30 
minutes. All the signals appearing in the spectra were integrated. 
The normalised peak area for the signal at 25 ppm (quintet in the 
coupled spectra, J=10.7 Hz), corresponding to the alkylated 
product, was then plotted against time and these data were used 5 
for kinetic fittings. 
N-thiophosphorylation of simple hydrophobic amine library 
and S-alkylation of the resulting N-thiophosphoramidate 
anions 20-33a-c. 
Details of quantities are summarized in tabular format in the 10 
Electronic Supplementary Information. 
 An amine (ESI table 3, RNH2) was mixed with sodium 
hydroxide solution   (5 Eq of a 1 M aqueous solution: 20-33a: 
0.9 mL, 0.9 mmol; 20-33b,c: 2.425 mL, 2.425 mmol) and water 
(20-33a: 0.116 mL; 20-33b,c: 0.312 mL) in a round-bottomed 15 
flask with indentations that aim to ensure turbulent mixing. 
Thiophosphoryl chloride (1 Eq, 20-33a: 0.18 mmol, 0.018 mL; 
20-33b,c: 0.049 mL, 0.485 mmol) dissolved in THF (20-33a: 
0.548 mL; 20-33b,c: 1.476 mL) was added dropwise to the 
aqueous mixture over the course of 10 min. After 1 h of vigorous 20 
mixing to allow N-thiophosphorylation to take place, an 
alkylating agent was added (ESI table 3) along with additional 
sodium hydroxide solution (ESI table 3) and vigorous mixing was 
continued fo either 1h (20-33a) or overnight (20-33b,c). Then, 
ether extraction was performed (20-33a: 3 × 5 mL; 20-33b,c: 25 
3 × 20 mL) and the aqueous layer was lyophilized. In the 
examples where a white precipitate appeared during the 
extraction, the sample was centrifuged and the precipitate was 
dried overnight in a vacuum desiccator before being analysed. 
The crude material was then subjected to 1H and 31P NMR 30 
analyses to assess conversion levels, and 13C NMR analyses were 
used to confirm the identity of the major product. 
Summary of Spectroscopic Data. 
20a 
 35 
δH(700 MHz; CD3OD) 8.78-8.75 (1 H, m, Ar-H), 8.20-8.17 (1 H, 
m, Ar-H), 7.82 (1 H, d, J 7.0, Ar-H), 7.73-7.67 (2 H, m, Ar-H), 
7.50 (1 H, br s, CF3CCHC), 7.48-7.32 (4 H, m, Ar-H) 4.56 (2 H, 
d, J 11.2, CH2NH), 3.80 (2 H, d, J 8.6, SCH2); δP[1H](283 MHz; 
CD3OD) 23.7-23.4 (m, NHPS); δF(376 MHz; CD3OD) –63.8 (s, 40 
CF3);  δC(176 MHz; CD3OD) 149.2, 145.7, 142.2 (d, 3JC-P 10.8, 
CCH2NH), 138.0 (m, 3JC-P not resolved, SCH2C), 136.5, 130.9, 
129.7, 128.7, 128.4, 126.9, 126.2-126.0 (m, 2JC-F not resolved, 
Ar), 124.9 (1JC-F 272, CF3), 123.9-123.7 (m, 3JC-F not resolved), 
122.8 (q, 3JC-F 3.0, Ar), 121.0, 45.6 (CH2NH), 30.0 (SCH2), the 45 
other peaks have not been resolved;  m/z (ES–) 411.0547 (M–H. 
C18H15N2O2F3PS requires 411.0549). 
20b 
 
δH(700 MHz; CD3OD) 7.61 (1 H, s, Ar(CF3)), 7.52 (1 H, d, J 7.6, 50 
Ar(CF3)), 7.46 (1 H, d, J 7.6, Ar(CF3)), 7.43 (1 H, t, J 7.6, 
Ar(CF3)), 7.32 (2 H, d, J 7.6, Ar-H), 7.23 (2 H, app t, J 7.5, Ar-
H), 7.15 (1 H, t, J 7.3, Ar-H), 3.91 (2 H, d, J 9.3, SCH2), 3.86 (2 
H, d, J 10.1, CH2NH); δP[1H](283 MHz; CD3OD) 22.3 (app qn, J 
9.3, NHPS); δF(376 MHz; CD3OD) –63.9 (s, CF3);  δC(176 MHz; 55 
CD3OD) 142.8-142.7 (m, Ar), 140.0-139.9 (m, Ar), 131.0, 130.0 
(q, 2JC-F 31), 128.45, 128.40, 127.9, 126.3, 124.4 (q, 1JC-F 272, 
CF3), 123.8-123.7 (m, 3JC-F, Ar), 122.9 (q, 3JC-F 3.8, Ar), 45.4 
(CH2NH), 34.6 (SCH2); m/z (ES–) 360.04420 (M–H. 
C15H14NO2F3PS requires 360.04405). 60 
20c 
 
δH(700 MHz; CD3OD) 7.83 (1 H, br s, Ar-H), 7.65 (1 H, d, J 6.8, 
Ar-H), 7.51-7.46 (2 H, m, Ar-H), 4.12 (2 H, d, J 10.1, SCH2), 
2.61 (2 H, dt, J 10.2 and 7.4, SCH2), 1.60 (2 H,  app sx, J 7.4, 65 
CH2CH3), 0.99 (3 H, t, J 7.4, CH2CH3); δP[1H](283 MHz; 
CD3OD) 23.7 (app qn, J 10.2, NHPS); δF(376 MHz; CD3OD) –
63.9 (s, CF3); δC(176 MHz; CD3OD) 142.9 (d, 3JC-P 7.4, 
CCH2NH), 131.0 (4-CH), 130.0 (q, 2JC-F 31.5, CCF3), 128.4 (5-
CH), 124.3 (q, JC-F 271, CF3), 123.9 (q, 3JC-F 3.2, 2-CH), 122.8(q, 70 
3JC-F 3.6, 6-CH), 45.4 (CH2NH), 32.3 (SCH2), 24.2 (d, 3JC-P 6.8, 
CH2CH3), 12.7 (CH2CH3); m/z (ES–) 312.04392 (M–H. 
C11H14NO2F3PS requires 312.04405). 
21a 
 75 
δH(500 MHz; CD3OD) 8.80 (1 H, dd, J 4.2 and 1.8, Ar-H), 8.21 
(1 H, dd, J 8.2 and 1.8, Ar-H), 7.81 (1 H, d, J 7.0, Ar-H), 7.74 (1 
H, dd, J 8.2 and 1.3, Ar-H), 7.59-7.24 (8 H, m, Ar-H), 7.22-7.20 
(2 H, m, Ar-H), 4.56 (2 H, d, J 11.2, CH2NH), 3.80 (2 H, d, J 8.2, 
SCH2); δP[1H](283 MHz; CD3OD) 23.8-23.6 (m, NHPS); δC(125 80 
MHz; CD3OD) 149.2, 145.8, 140.8, 140.1 (d, 3JC-p 10.5, 
CCH2NH), 139.3, 138.0 (d, 3JC-P 4.4, SCH2C), 136.6, 129.7, 
128.6, 128., 127.8, 126.8, 126.4, 126.3, 126.2, 126.0, 120.8, 45.5 
(CH2NH), 30.1 (SCH2); m/z (ES–) 419.0993 (M–H. 
C23H20N2O2PS requires 419.0988). 85 
21b 
 
δH(700 MHz; CD3OD) 7.57 (2 H, d, J 7.8, Ar-H), 7.50 (2 H, d, J 
7.8,  Ar-H), 7.40 (2 H, t, J 7.6, Ar-H), 7.35 (2 H, d, J 7.8, Ar-H), 
7.32-7.27 (3 H, m, Ar-H), 7.21 (2 H, d, J 7.5, Ar-H), 7.14 (1 H, t, 90 
J 7.5, Ar-H), 3.91 (2 H, d, J 9.0, NCH2), 3.85 (2 H, d, J 9.6, 
CH2S); δP[1H](283 MHz; CD3OD) 22.5 (app qn, J 9.3, NHPS); 
δC(176 MHz; CD3OD) 140.9, 140.5 (d, 3JC-p 8.5, CCH2NH), 
139.8 (d, 3JC-P 5.1, CCH2S), 139.5, 128.5, 128.4, 127.9, 127.8, 
126.7, 126.4, 126.4, 126.2, 45.6 (CH2NH), 34.6 (SCH2); m/z (ES–95 
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) 368.08796  (M – H. C20H19NO2PS requires 368.08796). 
21c 
 
δH(700 MHz; CD3OD) 7.57-7.56 (2 H, m,  Ar-H), 7.53-7.51 (2 H, 
m Ar-H), 7.47-7.45 (2 H, m, Ar-H), 7.39 (1 H, t, J 7.7, Ar-H), 5 
7.30-7.27 (1 H, m, Ar-H), 4.08 (2 H, d, J 9.8, CH2NH), 2.63 (2 H, 
dt, J 10.5 and 7.4, SCH2), 1.61 (2 H,  app sx, J 7.4, CH2CH3), 
0.95 (3 H, t, J 7.4, CH2CH3); δP[1H](283 MHz; CD3OD) 23.8 
(app qn, J 9.7, NHPS); δC(176 MHz; CD3OD) 140.9, 140.5 (d, 
3JC-p 8.5, CCH2NH), 139.5, 128.4, 127.8, 126.7, 126.4, 126.4, 10 
45.6 (CH2NH), 32.4 (SCH2), 24.2 (d, 3JC-P 6.7, CH2CH3), 12.8 
(CH2CH3); m/z (ES–) 320.08799 (M–H. C16H19NO2PS requires 
320.08796). 
22a 
 15 
δH(700 MHz; CD3OD) 8.72 (1 H, dd, J 4.2 and 1.7, Ar-H), 8.12 
(1 H, dd, J 8.3 and 1.7, Ar-H), 8.02 (1 H, d, J 8.1, Ar-H), 7.79 (1 
H, d, J 7.0, Ar-H), 7.78 (1 H, d, J 7.9, Ar-H), 7.68-7.60 (2 H, m, 
Ar-H), 7.37-7.31 (4 H, m, Ar-H), 7.27-7.24 (1 H, m, Ar-H), 7.18 
(1 H, d, J 6.8, Ar-H), 4.57 (2 H, d, J 11.1, CH2NH), 4.18 (2 H, d, 20 
J 7.0, SCH2); δP[1H](283 MHz; CD3OD) 23.6-23.5 (m, NHPS); 
δC(176 MHz; CD3OD) 149.4, 146.0, 138.3 (d, 3JC-P 3.3, SCH2C), 
136.9), 136.1 (d, 3JC-P 11, CCH2NH), 133.7, 131.4, 129.6, 128.5, 
127.9, 127.1, 126.9, 126.0, 125.4, 125.1, 125.0, 124.9, 123.5, 
43.6 (CH2NH), 32.2 (SCH2); m/z (ES–) 393.0834 (M–H. 25 
C21H18N2O2PS requires 393.0832). 
22b 
 
δH(700 MHz; CD3OD) 8.15 (1 H, d, J 8.5, Ar-H), 7.82 (1 H, d, J 
8.0, Ar-H), 7.72 (1 H, d, J 8.1, Ar-H), 7.48-7.42 (2 H, m, Ar-H), 30 
7.40-7.38 (1 H, m, 2-CH), 7.37-7.33 (3 H, m, Ar-H), 7.23 (2 H, 
app t, J 7.6, Ar-H), 7.15 (1 H, t, J 7.4, Ar-H), 4.30 (2 H, d, J 7.4, 
CH2NH), 4.30 (2 H, d, J 10.2, SCH2); δP[1H](283 MHz; CD3OD) 
22.4-22.2 (m, NHPS); δC(176 MHz; CD3OD) 140.2 (d, 3JC-p 4.0, 
CH2S), 136.3 (d, 3JC-P 9.0, CH2NH), 133.9, 131.5, 128., 128.0, 35 
127.2, 127.1, 126.3, 125.5, 125.23, 125.15, 125.0,  123.5, 43.6 
(CH2NH), 34.6 (SCH2); m/z (ES–) 342.07236 (M–H. 
C18H17NO2PS requires 342.07231). 
22c 
 40 
δH(700 MHz; CD3OD) 8.24 (1 H, d, J 8.4, Ar-H), 7.84 (1 H, d, J 
8.1, Ar-H), 7.75 (1 H, d, J 8.3, Ar-H), 7.57 (1 H, d, J 7.1, Ar-H), 
7.50 (1 H, ddd, J 8.3, 6.8 and 1.3, 7-CH), 7.43 (1 H, ddd, J 8.4, 
6.8 and 1.3, Ar-H), 7.40 (1 H, dd, J 8.1, 7.1, Ar-H), 4.51 (2 H, d, 
J 7.7, CH2NH), 2.64 (2 H, dt, J 10.5 and 7.4, SCH2), 1.63 (2 H, 45 
app sx, J 7.4, CH2CH3), 0.95 (3 H, t, J 7.4, CH2CH3); δP[1H](283 
MHz; CD3OD) 23.8-23.6 (m, NHPS); δC(176 MHz; CD3OD) 
136.3 (d, 3JC-P 9.0, CCH2NH), 133.9, 131.5, 128.1, 127.2, 125.5, 
125.2, 125.1, 125.0, 123.5, 43.6 (CH2NH), 32.2 (SCH2), 24.0 (d, 
3JC-P 6.5, CH2CH3), 12.5 (CH2CH3);  m/z (ES–) 294.07232 (M–H. 50 
C14H17NO2PS requires 294.07231). 
23a 
 
δH(700 MHz; CD3OD) 8.77-8.75 (1 H, m, Ar-H), 8.18-8.16 (1 H, 
m, Ar-H), 7.76 (1 H, d, J 7.1, Ar-H), 7.68 (1 H, d, J 8.1, Ar-H), 55 
7.52-7.48 (2 H, m, Ar-H), 7.41-7.37 (2 H, m, Ar-H), 7.24 (1 H, t, 
J 7.5, Ar-H), 7.14 (1 H, t, J 7.5, Ar-H), 7.10 (1 H, t, J 7.5, Ar-H), 
7.06 (1 H, t, J 7.6, Ar-H), 6.96-6.92 (2 H, m, Ar-H), 4.62 (2 H, s, 
CH2OH), 4.52 (2 H, d, J 11.0, CH2NH), 3.92 (2 H, d, J 8.9, 
SCH2); δP[1H](283 MHz; CD3OD) 23.9-23.8 (m, NHPS); δC(125 60 
MHz; CD3OD) 149.2, 145.7, 141.9, 136.6, 133.0, 132.8, 141.3 (d, 
3JC-P 11.2,  CCH2NH), 129.7, 129.1, 128.4, 127.9, 127.5, 127.5, 
127.4), 127.3, 127.1, 120.9, 61.7 (CH2OH), 44.0 (CH2NH), 30.1 
(SCH2); m/z (ES–) 481.0822 (M–H. C24H22N2O2PS requires 
481.0815). 65 
23b 
 
δH(700 MHz; CD3OD) 7.56 (1 H, d, J 7.7, Ar-H), 7.54 (1 H, d, J 
7.7, Ar-H), 7.28-7.10 (9 H, m, Ar-H), 7.06-7.02 (2 H, m, Ar-H), 
4.71 (2 H, s, CH2OH), 4.06 (2 H, d, J 9.4, CH2NH), 3.81 (2 H, d, 70 
J 9.4, SCH2); δP[1H](283 MHz; CD3OD) 22.6 (app qn, J 9.4, 
NHPS);  δC(176 MHz; CD3OD) 141.9 (CCH2OH), 139.9 (i-
C6H5CH2S), 133.0, 132.8, 131.3 (d, 3JC-P 8.1, CCH2NH), 128.8–
126.4 (12 × s), 126.5, 61.3 (CH2OH), 46.1 (CH2NH), 35.4 
(SCH2);  m/z (ES–) 430.07103 (M–H. C21H21NO3PS2 requires 75 
430.07059). 
23c 
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δH(700 MHz; CD3OD) 7.64 (1 H, d, J 7.7, Ar-H), 7.54 (1 H, d, J 
7.7, Ar-H), 7.28 (1 H, t, J 7.5, Ar-H), 7.25 (1 H, t, J 7.5, Ar-H), 
7.17 (1 H, t, J 7.5, Ar-H), 7.14 (1 H, t, J 7.5, Ar-H), 7.06 (1 H, d, 
J 7.7, Ar-H), 7.05 (1 H, d, J 7.7, Ar-H), 4.72 (2 H, s, CH2OH), 5 
4.17 (2 H, d, J 9.4, CH2NH), 2.56 (2 H, dt, J 10.5 and 7.4, SCH2), 
1.60 (2 H, app sx, J 7.4, CH2CH3), 0.90 (3 H, t, J 7.4, CH2CH3); 
δP[1H](283 MHz; CD3OD) 23.9 (app qn, J 9.8, NHPS); δC(176 
MHz; CD3OD) 141.9 (CCH2OH), 133.0, 132.8, 131.3 (d, 3JC-P 
11.2,  CCH2NH), 129.1,  127.9, 127.5, 127.4,  127.3, 62.3 10 
(CH2OH), 46.1 (CH2NH), 35.4 (SCH2), 27.2 (d, 3JC-P 6.2, 
CH2CH3), 16.8 (CH2CH3); m/z (ES–) 382.07098 (M–H. 
C17H21NO3PS2 requires 382.07060). 
24a 
 15 
δH(700 MHz; CD3OD) 8.66 (1 H, dd, J 4.1 and 1.7, Ar-H), 8.24 
(1 H, d, J 9.2, Ar-H), 8.11 (1 H, d, J 7.5, Ar-H), 8.10 (1 H, d, J 
7.6, Ar-H), 7.99-7.89 (6 H, m, Ar-H), 7.76 (1 H, d, J 7.0, Ar-H), 
7.73 (1 H, d, J 7.7, Ar-H), 7.53 (1 H, d, J 8.2, Ar-H), 7.32-7.29 (1 
H, m, Ar-H), 7.21 (1 H, dd, J 8.2 and 4.1, Ar-H), 4.58 (2 H, d, J 20 
11.7, CH2NH), 4.44 (2 H, d, J 7.4, SCH2); δP[1H](283 MHz; 
CD3OD) 23.4-23.2 (m, NHPS); δC(125 MHz; CD3OD) 149.3, 
145.9, 137.8 (d, 3JC-P not resolved, SCH2C), 134.0 (d, 3JC-P 11.2, 
CCH2NH), 136.6, 131.3, 130.8, 130.5, 128.5, 129.5, 128.4, 127.0, 
126.7, 126.3, 126.1, 125.4, 125.8, 124.4, 124.4, 124.2, 123.2, 25 
120.7, 44.0 (CH2NH), 30.1 (SCH2); m/z (ES–) 467.0996 (M–H. 
C27H20N2O2PS requires 467.0988). 
24b 
 
δH(700 MHz; CD3OD) 8.39 (1 H, d, J 9.2, Ar-H), 8.14 (1 H, t, J 30 
7.5, Ar-H), 8.09-8.05 (1 H, m, Ar-H), 8.06 (1 H, d, J 7.7, Ar-H), 
8.00 (1 H, s, Ar-H), 7.97-7.93 (1 H, m, Ar-H), 7.30 (1 H, d, J 7.3, 
Ar-H), 7.18 (1 H, t, J 7.6, Ar-H), 7.12 (1 H, t, J 7.4, Ar-H), 4.56 
(2 H, d, J 7.7,  CH2NH), 3.89 (2 H, d, J 10.2, SCH2); δP[1H](283 
MHz; CD3OD) 22.6-22.3 (m, NHPS);  δC(176 MHz; CD3OD) 35 
140.1 (CCH2NH), 134.2 (CH2S), 131.3, 130.8, 130.5, 128.5, 
128.4, 127.9, 127.0, 126.9, 126.5, 126.4, 126.2, 125.5, 124.5, 
124.4, 123.1, 43.7 (CH2NH), 34.5 (SCH2); m/z (ES–) 416.08815 
(M–H. C24H19NO2PS requires 416.08796). 
24c 40 
 
δH(700 MHz; CD3OD) 8.39 (1 H, d, J 9.2, ArH), 8.16-8.13 (2 H, 
m, Ar-H), 8.12-8.11 (2 H, m, Ar-H), 8.09 (1 H, d, J 9.2, Ar-H), 
8.01-7.99 (2 H, m, Ar-H), 7.96 (1 H, t, J 7.6, Ar-H), 4.46 (2 H, d, 
J 7.7, CH2NH), 2.63 (2 H, dt, J 9.8 and 7.4, SCH2), 1.60 (2 H, 45 
app sx, J 7.4, CH2CH3), 0.94 (3 H, t, J 7.4, CH2CH3); δP[1H](283 
MHz; CD3OD) 23.7-23.5 (m, NHPS);  δC(176 MHz; CD3OD) 
134.4 ( d, 3JC-P 11.7, CCH2NH), 131.3, 130.8, 130.5, 128.5, 
127.0, 126.9, 126.5, 126.4, 125.5, 124.5, 124.4, 124.3, 44.1 
(CH2NH), 32.5 (SCH2), 24.2 (d, 3JC-P  6.7, CH2CH3), 12.7 50 
(CH2CH3); m/z (ES–) 368.08837 (M–H. C20H19NO2PS requires 
368.08796). 
25a 
 
δH(700 MHz; CD3OD) 8.67 (1 H, dd, J 4.1 and 1.7, Ar-H), 8.23 55 
(1 H, d, J 9.1, Ar-H), 8.08 (2 H, t, J 7.7, Ar-H), 7.99-7.89 (6 H, 
m, Ar-H), 7.76 (1 H, d, J 7.0, Ar-H), 7.74 (1 H, d, J 7.7, Ar-H), 
7.53 (1 H, d, J 8.1, Ar-H), 7.32-7.29 (1 H, m Ar-H), 7.20 (1 H, 
dd, J 8.2 and 4.1, Ar-H), 4.59 (2 H, d, J 11.5, CH2N), 4.44 (2 H, 
d, J 7.4, SCH2), 3.30-3.28 (3 H, m, NCH3); δP[1H](283 MHz; 60 
CD3OD) 23.3-23.1 (m, NPS); δC(176 MHz; CD3OD) aromatic 
signals could not be assigned owing to the level of heterogeneity 
of this particular sample, 43.8 (CH2N), 38.6-37.8 (m, NCH3), 
29.9 (SCH2); m/z (ES–) 457.1153 (M–H. C26H22N2O2PS requires 
457.1145). 65 
25b 
 
δH(700 MHz; CD3OD) 8.60 (2 H, d, J 8.8, Ar-H), 8.40 (1 H, s, 
Ar-H), 7.97 (2 H, d, J 8.5, Ar-H), 7.52 (2 H, d, J 7.5, Ar-H), 7.49-
7.45 (2 H, m, Ar-H), 7.43-7.40 (2 H, m, Ar-H), 7.33 (2 H, t, J 70 
7.6,Ar-H), 7.26 (1 H, t, J 7.4, Ar-H), 5.01 (2 H, d, J 3.8,  
CH2NH), 4.15 (2 H,  d, J 10.1,  SCH2), 2.21 (3 H, d, J 12.2, 
NCH3); δP[1H](283 MHz; CD3OD) 23.7-23.4 (m, NHPS);  
δC(176 MHz; CD3OD) 140.9 (d, 3JC-p 5.4), 131.7, 131.6, 129.7 (d, 
3JC-P 10.7), 128.7, 128.5, 127.6, 127.3, 126.3, 125.5, 124., 124.7, 75 
44.5 (CH2NH), 34.3 (SCH2), 32.4 (NCH3); m/z (ES–) 406.10419 
(M–H. C23H21NO2PS requires 406.10361). 
25c 
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δH(700 MHz; CD3OD) 8.74 (2 H, d, J 8.9, Ar-H), 8.42 (1 H, s, 
Ar-H), 7.99 (2 H, d, J 8.4, Ar-H), 7.50 (2 H, 2 × t, J 7.4, 2- and 7-
CH), 7.51-7.48 (2 H, m, Ar-H), 7.44-7.41 (2 H, m, Ar-H) 5.17 (2 
H, d, J 3.7,  CH2NH), 2.85 (2 H, dt, J 9.8 and 7.4, SCH2), 2.30 (3 5 
H, d, J 12.1, NCH3), 1.75 (2 H,  app sx, J 7.4, CH2CH3), 1.04 (3 
H, t, J 7.4, CH2CH3); δP[1H](283 MHz; CD3OD) 24.9-24.6 (m, 
NHPS); δC(176 MHz; CD3OD) 131.5, 131.4, 129.4 (d, 3JC-P 9.1), 
128.5, 127.1, 125.3, 124.8, 124.4, 44.2 (CH2NH), 32.4 (SCH2), 
31.8 (NCH3), 24.7 (d, 3JC-P  5.5, CH2CH3), 12.7 (CH2CH3);  m/z 10 
(ES–)  358.10394 (M–H. C19H21NO2PS requires 358.10361). 
26a 
 
δH(700 MHz; CD3OD) 8.79 (1 H, dd, J 4.2 and 1.8, Ar-H), 8.21 
(1 H, dd, J 8.2 and 1.8, Ar-H), 7.71 (1 H, dd, J 8.2 and 1.3, Ar-15 
H), 7.62-7.60 (1 H, m, Ar-H), 7.43 (1 H, dd, J 8.2 and 4.2, Ar-H), 
7.39 (1 H, dd, J 8.1 and 7.2, Ar-H), 7.10-6.96 (8 H, m, Ar-H), 
6.81-6.79 (2 H, m, Ar-H), 4.51 (1 H, J 12.7 and 9.6, SCH2), 4.40-
4.35 (1 H, m, CH2CH), 4.31 (1 H, J 12.7 and 10.3, SCH2), 3.19 (1 
H, J 13.1 and 4.6, CH2CH ), 2.74 (1 H, J 13.1 and 9.5, CH2CH); 20 
δP[1H](283 MHz; CD3OD) 21.7-21.5 (m, NHPS); δC(176 MHz; 
CD3OD) 149.2, 149.0, 145.9, 144.1-144.0 (unresolved, CCHNH), 
138.5, 137.8-137.7 (unresolved, SCH2C), 136.6, 136.4, 129.7-
125.8 (11 × s), 120.9, 120.7, 57.9-57.6 (unresolved, CH2CH),  
45.1-44.9 (unresolved, CH2CH), 30.1-29.8 (unresolved, SCH2); 25 
m/z (ES–) 433.1143 (M–H. C24H22N2O2PS requires 433.1145). 
26b 
 
δH(700 MHz; CD3OD) 7.19-7.03 (13 H, m, Ar-H), 6.95-6.92 (2 
H, m, Ar-H), 4.46 (1 H, ddd, J 11.2, 9.2 and 5.2, CH2CH), 3.60 (1 30 
H, J 12 and 6.9, SCH2), 3.47 (1 H, J 12 and 7.7, SCH2),  3.22 (1 
H, J 13.1 and 5.2, CH2CH), 2.88 (1 H, J 13.1 and 9.0, CH2CH ); 
δP[1H](283 MHz; CD3OD) 20.9-20.8 (m, NHPS); δC(176 MHz; 
CD3OD) 144.4 (d, 3JC-P 3.7, CCHNH), 139.2 (d, 3JC-P 7.8, 
SCH2C), 138.5, 129.5-125.5 (6 × s), 57.7 (CH2CH), 45.7-45.4 35 
(unresolved, CH2CH), 34.5-34.3 (unresolved, SCH2); m/z (ES–)  
382.10338 (M – H. C21H21NO2PS requires 382.10361). 
26c 
 
δH(700 MHz; CD3OD) 7.18-7.03 (8 H, m, Ar-H), 6.97-6.94 (2H, 40 
m, Ar-H), 4.45 (1 H,  ddd, J 14.0, 11.2 and 5.6, CH2CH), 3.22 (1 
H, J 13.2 and 5.3,  CH2CH ), 2.93 (1 H, CH2CH), 2.37-2.22 (m, 
SCH2), 1.42-1.32 (2 H, m, CH2CH3), 0.79 (3 H, t, J 7.4, CH3); 
δP[1H](283 MHz; CD3OD) 22.4-22.3 (m, NHPS); δC(176 MHz; 
CD3OD) 144.4 (d, 3JC-P  not resolved, CCHNH), 138.5, 129.4, 45 
127.4 (2 × s), 126.8, 126.0, 125.5, 57.6 (CH2CH), 45.5 (d, 3JC-P  
5.6, CH2CH), 32.0 (SCH2), 23.6 ( d, 3JC-P  7.4, CH2CH3), 12.5 
(CH3);  m/z (ES–) 334.10399 (M–H. C17H21NO2PS requires 
335.10361). 
27a 50 
 
δH(700 MHz; CD3OD) 8.80 (1 H, dd, J 4.2 and 1.7, Ar-H), 8.25 
(1 H, dd, J 8.2 and 1.7, Ar-H), 7.82 (1 H, d, J 7.1, Ar-H), 7.76 (1 
H, d, J 8.1, Ar-H), 7.49-7.42 (2 H, m, Ar-H), 7.20-7.11 (5 H, m, 
Ar-H), 4.55 (2 H, d, J 11.2, SCH2), 3.74 (2 H, d, J 7.7, CH2NH); 55 
δP[1H](283 MHz; CD3OD) 23.7-23.5 (m, NHPS); δC(176 MHz; 
CD3OD) 149.2, 145.8, 141.0-140.8 (m, 3JC-P not resolved, 
CCH2NH), 138.2-138.0 (m, 3JC-P not resolved, SCH2C), 136.6, 
129.7, 128.6, 127.7, 127.2, 126.9, 126.1 (2 × s), 120.9, 45.8 
(CH2NH), 29.8 (SCH2); m/z (ES–) 343.0678 (M–H. 60 
C17H16N2O2PS requires 343.0678). 
28a 
 
δH(500 MHz; CD3OD) 8.89 (1 H, dd, J 4.2 and 1.8, Ar-H), 8.30 
(1 H, dd, J 8.3 and 1.7, Ar-H), 7.90-7.86 (1 H, m, Ar-H), 7.82 (1 65 
H, dd, J 8.2 and 1.3, Ar-H), 7.56-7.49 (2 H, m, Ar-H), 5.83-5.72 
(1 H, m, CH2=CH), 4.99 (1 H, dq, J 17.1 and 1.7, CHH=CH), 
4.91-4.87 (1H, m, CHH=CH), 4.57 (2 H, d, J 11.1, SCH2), 3.23 
(2 H, ddt, J 8.8, 5.7 and 1.5, CH2NH); δP[1H](283 MHz; CD3OD) 
23.8-23.6 (m, NHPS); δC(125 MHz; CD3OD) 149.5, 146.0, 138.3 70 
(d, 3JC-P 4.6, SCH2C), 137.5 (d, 3JC-P 9.9, CHCH2), 136.9, 130.0, 
128.9, 127.2, 126.4, 121.2, 113.7 (CH2=CH), 44.8 (CH2NH), 30.0 
(d, 2JC-P 2.7, SCH2); m/z (ES–) 293.0522 (M–H. C13H14N2O2PS 
requires 293.0519). 
29a 75 
 
δH(500 MHz; CD3OD) 8.89 (1 H, dd, J 4.2 and 1.8, Ar-H), 8.30 
(1 H, dd, J 8.3 and 1.7, Ar-H), 7.89 (1 H, dd, J 7.1 and 1.0, Ar-
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H), 7.82 (1 H, dd, J 8.2 and 1.2, Ar-H), 7.56-7.49 (2H, m, Ar-H), 
4.56 (2 H, d, J 11.1, SCH2), 2.57 (2 H, dt, J 8.7 and 7.4, CH2NH), 
1.30 (2 H, app sx, J 7.4, CH3CH2), 0.77 (3 H, t, J 7.4, CH3CH2); 
δP[1H](283 MHz; CD3OD) 24.2-24.0 (m, NHPS); δC(125 MHz; 
CD3OD) 149.5, 146.1, 138.3 (d, 3JC-P 4.6, SCH2C), 136.9, 129.9, 5 
128.8, 127.2, 126.4, 121.2, 43.8 (CH2NH), 30.1 (d, 2JC-P 2.7, 
SCH2), 24.4 (d, 2JC-P 9.1, CH3CH2), 10.7 (CH3CH2); m/z (ES–) 
295.0677 (M–H. C13H16N2O2PS requires 295.0675) 
29b 
 10 
δH(700 MHz; CD3OD) 7.38 (2 H, d, J 7.3, Ar-H), 7.28 (2 H, t, J 
7.6, Ar-H), 7.21 (1 H, t, J 7.3, Ar-H), 3.89 (2 H, d, J 9.9, SCH2), 
2.68 (2 H, dt, J 8.7 and 7.4, CH2NH), 1.39 (2 H, app sx, J 7.4, 
CH3CH2), 0.86 (3 H, t, J 7.4, CH3CH2); δP[1H](283 MHz; 
CD3OD) 23.1 (app qn, J 9.5, NHPS); δC(176 MHz; CD3OD) 15 
140.2 (d, 3JC-P 6.1, SCH2C ), 128.7, 128.2, 126.5, 43.8 (CH2NH), 
34.6 (d, 2JC-P 2.8, SCH2), 24.5 (d, 3JC-P 8.8, CH3CH2), 10.7 
(CH3CH2);  m/z (ES–) 244.05622 (M–H. C10H15NO2PS requires 
244.05666). 
30a 20 
 
δH(700 MHz; CD3OD) 8.81 (1 H, dd, J 4.2 and 1.6, Ar-H), 8.37 
(1 H, d, J 4.3, Ar-H), 8.23 (1 H, dd, J 8.2 and 1.4, Ar-H), 7.82 (1 
H, d, J 7.0, Ar-H), 7.74 (1 H, d, J 8.0, Ar-H), 7.65 (1 H, td, J 7.7 
and 1.7, Ar-H), 7.47-7.42 (2 H, m, Ar-H), 7.20 (1 H, d, J 7.8, Ar-25 
H), 7.17 (1 H, dd, J 6.9 and 5.5, Ar-H), 4.50 (2 H, d, J 10.4, 
SCH2), 3.05-2.99 (2 H, m, CH2CH2NH), 2.81 (2 H, t, J 7.2, 
CH2CH2NH); δP[1H](283 MHz; CD3OD) 23.6 (app qn, J 10.1, 
NHPS); δC(176 MHz; CD3OD) 160.0, 149.2, 148.2, 145.8, 137.9-
137.8 (m, 3JC-P not resolved, SCH2C), 137.0, 136.6, 129.7, 128.5, 30 
126.9, 126.1, 123.6, 121.5, 120.9, 41.6 (CH2NH), 39.1 (d, 3JC-P 
7.6, CH2CH2NH), 30.2 (SCH2); m/z (ES–) 358.0786 (M–H. 
C17H17N3O2PS requires 358.0784). 
30c 
 35 
δH(700 MHz; CD3OD) 8.42 (1 H, ddd, J 5.0, 1.7 and 0.9, Ar-H), 
7.74 (1 H, td, J 7.7 and 1.8, Ar-H), 7.37 (1 H, d, J 7.8, Ar-H), 
7.24 (1 H, ddd, J 7.5, 5.0 and 1.0, Ar-H), 3.22 (2 H, dt, J 9.8 and 
7.1, CH2CH2NH), 2.98 (2 H, t, J 7.1, CH2CH2NH), 2.55 (2 H, dt, 
J 10.3 and 7.3, SCH2), 1.58 (2 H, app sx, J 7.4, CH2CH3), 0.93 (3 40 
H, t, J 7.4,  CH2CH3); δP[1H](283 MHz; CD3OD) 24.0 (app qn, J 
10.1, NHPS); δC(176 MHz; CD3OD) 159.9, 148.2, 137.1, 123.8, 
121.5, 41.6 (CH2CH2NH), 39.2 (d, 3JC-P 8.0, CH2CH2NH), 32.1 ( 
SCH2), 23.9 (d, 3JC-P  6.4, CH2CH3), 12.5 (CH2CH3);  m/z (ES–) 
259.06778 (M–H. C10H16N2O2PS requires 259.06756). 45 
31a 
 
δH(700 MHz; CD3OD) 8.83 (1 H, dd, J 4.0 and 1.3, Ar-H), 8.27-
8.24 (1 H, m, Ar-H), 7.88 (1 H, d, J 7.0, Ar-H), 7.76 (1 H, d, J 
8.0, Ar-H), 7.57 (1 H, d, J 7.6, Ar-H), 7.51-7.43 (2 H, m, Ar-H), 50 
7.01-6.98 (1 H, m, Ar-H), 6.95-6.91 (2 H, m, Ar-H), 4.64-4.61 (2 
H, m, SCH2), 4.30-4.25 (1 H, m, CHNH), 2.70-2.55 (2 H, m, 3-
CH2), 1.95–1.87 (1 H, m, CHH), 1.79-1.71 (1 H, m, CHH), 1.68–
1.55 (2 H, m, CH2); δP[1H](283 MHz; CD3OD) 21.3 (app q, J 
10.3, NHPS); δC(176 MHz; CD3OD) 149.2, 146.0, 140.0-139.8 55 
(m, 3JC-P  not resolved, CCHNH), 138.0-137.9 (m, 3JC-P not 
resolved, SCH2C), 136.8, 136.5, 129.7, 128.9, 128.6, 128.0, 
126.9, 126.2, 125.9, 125.2, 120.9, 49.7 (CHNH), 31.9, 30.3 (d, 
3JC-P 2.6), 29.0 (SCH2), 19.7; m/z (ES–) 383.0987 (M–H. 
C20H20N2O2PS requires 383.0988). 60 
31c 
 
δH(700 MHz; CD3OD) 7.63 (1 H, d, J 7.2, Ar-H), 7.09-7.03 (2 H, 
m, Ar-H), 6.99 (1 H, d, J 7.3, Ar-H), 4.34-4.29 (1 H, m, CHNH), 
2.80-2.64 (4 H, m, 3-CH2 and SCH2), 2.11-2.04 (1 H, m, 4-CH2), 65 
1.96-1.89 (1 H, m, 4-CH2), 1.89-1.82 (1 H, m, 2-CH2), 1.78-1.62 
(4 H, m, 2-CH2 and CH2CH3), 0.99 (3 H, t, J 7.4, CH2CH3); 
δP[1H](283 MHz; CD3OD) 22.2-22.0 (m, NHPS); δC(176 MHz; 
CD3OD) 140.1-140.0 (m, CCHNH), 136.7, 128.9, 128.1, 126.0, 
125.2, 49.7 (CHNH), 32.5 (2-CH), 32.3 (SCH2), 29.0 (4-CH), 70 
23.9 (d, 3JC-P  7.0, CH2CH3), 19.8 (3-CH), 12.6 ( CH2CH3);  m/z 
(ES–) 284.08826 (M–H. C13H19NO2PS requires).  
32a 
 
δH(700 MHz; CD3OD) 8.86 (1 H, dd, J 4.2 and 1.7, Ar-H), 8.26 75 
(1 H, dd, J 8.2 and 1.7, Ar-H), 7.87 (1 H, d, J 7.0, Ar-H), 7.78 (1 
H, d, J 8.2, Ar-H), 7.52-7.46 (2 H, m, Ar-H), 4.54 (2 H, d, J 10.8, 
SCH2), 3.60 (4 H, t, J 4.6, O(CH2)2), 2.67 (2 H, dt, J 9.3 and 7.0, 
PNHCH2), 2.30 (4 H, br s, (CH2)2N), 2.24-2.20 (2 H, m, NCH2), 
1.50-1.44 (2 H, m, CH2CH2CH2); δP[1H](283 MHz; CD3OD) 23.8 80 
(app qn, J 10.1, NHPS); δC(176 MHz; CD3OD) 149.2, 145.9, 
138.2-138.0 (m, SCH2C), 136.6, 129.6, 128.5, 126.9, 126.1, 
121.0, 66.2 (O(CH2)2), 56.6 (NCH2), 53.3 ((CH2)2N),  40.2 
(CH2NH), 29.9 (SCH2), 27.3 (d, 3JC-P 7.5, CH2CH2NHP); m/z 
(ES–)  380.1202 (M–H. C17H23N3O3PS requires 380.1203). 85 
32c 
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δH(700 MHz; CD3OD) 3.70-3.66 (4 H, m, O(CH2)2),  2.91 (2 H, 
dt, J  9.6 and 6.8, SCH2), 2.63 (2 H, dt, J 10.3 and 7.3, CH2NH), 
2.46 (4 H, br s, (CH2)2N), 2.44-2.40 (2 H, m, NCH2), 1.75-1.65 (2 
H, m, CH2CH2CH2), 1.65-1.60 (2 H, m, CH2CH3), 0.97 (3 H, t, J 5 
7.4, CH2CH3); δP[1H](283 MHz; CD3OD) 24.2 (app qn, J 9.9, 
NHPS); δC(176 MHz; CD3OD) details for major conformer 66.3 
(O(CH2)2), 56.8 (NCH2), 53.4 ((CH2)2N), 40.2 (CH2NH), 32.1 
(SCH2), 27.8-27.4 (m, CH2CH2CH2), 24.2-23.8 (m, CH2CH3), 
12.7-12.5 (m, CH2CH3); m/z (ES–) 281.10967 (M–H. 10 
C10H22N2O3PS requires 281.10943). 
33a 
 
δH(700 MHz; CD3OD) 8.79 (1 H, dd, J 4.2 and 1.7, Ar-H), 8.23 
(1 H, dd, J 8.2 and 1.7, Ar-H), 7.81 (1 H, d, J 7.0, Ar-H), 7.74 (1 15 
H, d, J 8.2, Ar-H), 7.47-7.44 (1 H, m, Ar-H), 7.42 (1 H, dd, J 8.2 
and 4.2, Ar-H), 7.16-7.12 (2 H, m, Ar-H), 6.98 (2 H, t, J 8.8, Ar-
H), 4.54 (2 H, d, J 11.1, CH2NH), 3.73 (2 H, d, J 8.3, SCH2); 
δP[1H](283 MHz; CD3OD) 23.6-23.4 (m, NHPS); δF(376 MHz; 
CD3OD) –(118.8-119.0) (m, Ar-F); δC(176 MHz; CD3OD) 162.4, 20 
149.2, 145.8, 138.1-137.9 (m, PSCH2C), 137.0-136.8 (m, 
CCH2NHP), 136.6, 129.7, 129.0 (d, 3JC-F, 8.0), 128.6, 126.9, 
126.1, 121.0, 114.2 (d, 2JC-F, 21.4), 45.0 (CH2NH), 29.8 (SCH2); 
m/z (ES–) 361.0583 (M–H. C17H15N2O2FPS requires 361.0581). 
33c 25 
 
δH(700 MHz; CD3OD) 7.41-4.37 (2 H, m, Ar-H), 7.00-6.95 (2 H, 
m, Ar-H), 4.02 (2 H, d, J 9.4, CH2NH), 2.61 (2 H, dt, J 10.3 and 
7.3, SCH2), 1.61 (2 H, app sx, J 7.4, CH2CH3), 0.95 (3 H, t, J 7.4,  
CH2CH3); δP[1H](283 MHz; CD3OD) 23.8 (app qn, J 9.8 NHPS); 30 
δF(376 MHz; CD3OD) –(118.9-119.1) (m, Ar-F); δC(176 MHz; 
CD3OD) 161.8 (d, JC-F 242.5, FC), 137.4 (d, 3JC-P 8.0, CCH2NH), 
129.0 (d, 3JC-F, 8.0, 3-CH and 5-CH), 114.2 (d, 2JC-F, 21.5, 2-CH 
and 6-CH), 45.0 (CH2NH), 32.1 (SCH2), 24.0 (d, 3JC-P  6.4, 
CH2CH3), 12.5 (CH2CH3); m/z (ES–) 262.04744 (M – H. 35 
C10H14NO2FPS requires 262.04724) 
34 
 
δH(500 MHz; CD3OD) 8.87-8.84 (1 H, m, Ar-H), 8.29-8.25 (1 H, 
m, Ar-H), 8.00-7.96 (1 H, m, Ar-H), 7.77-7.74 (1 H, m, Ar-H), 40 
7.53-7.44 (2 H, m, Ar-H), 4.66-4.62 (2 H, m, SCH2); δP[1H](283 
MHz; CD3OD) 18.1 (t, 3JH-P 6.9, NHPS); δC(125 MHz; CD3OD) 
149.1, 146.1, 138.8 (d, 3JC-P 7.0, SCH2C), 136.7, 130.1, 128.5, 
126.4, 126.3, 120.7, 43.4 (CH2NH); m/z (ES–) 254.0047 (M–H. 
C10H9NO2PS requires 254.0046). 45 
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